We identified novel targets including CLTC (clathrin heavy chain), TNS2, PLCG1 and NIFK (nucleolar protein interacting with the FHA domain of MKI67) for specific therapy of diabetes mellitus and obesity. Here, MKI67 is linked to obesity disorder.